Epigenetics alterations occur in many human diseases, including cancer. Investigating epigenetic modifications in disease settings offers us valuable insights into underlying signaling pathways and disease progression, eventually contributing to the development of targeted therapies. See how we can help you study epigenetics in the context of cancer and other diseases. Take a look at our latest webinars, guides, and posters covering such topics as cancer epigenetics, histone mutations, epigenetics in drug development and diagnostics, and many others. To support ongoing drug discovery efforts, we provide an extensive portfolio of proteomic tools, from recombinant antibodies and proteins to ELISA kits and cell lines, to key targets in cancer epigenetics disease areas, including acute myeloid leukemia (AML), colorectal, prostate and breast cancers, glioma, melanoma and lung cancer (NSCLC).